Chinese Journal of Cancer Research

, Volume 24, Issue 4, pp 304–309

Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer

Original Article

DOI: 10.1007/s11670-012-0268-7

Cite this article as:
Zheng, H. & Gao, Y. Chin. J. Cancer Res. (2012) 24: 304. doi:10.1007/s11670-012-0268-7

Abstract

Objectives

To compare the survival and perioperative morbidity between primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NAC/IDS) in treating patients with advanced epithelial ovarian cancer (EOC).

Methods

We retrospectively reviewed 67 patients with stage IIIC or IV EOC treated at Peking University Cancer Hospital from January 2006 to June 2009. Wherein, 37 and 30 patients underwent PDS and NAC/ IDS, respectively.

Results

No difference in overall survival (OS) or progression-free survival (PFS) was observed between NAC/IDS group and PDS group (OS: 41.2 vs. 39.1 months, P=0.23; PFS: 27.1 vs. 24.3 months, P=0.37). The optimal debulking rate was 60% in the NAC/IDS group, which was significantly higher than that in the PDS group (32.4%) (P=0.024). The NAC/IDS group had significantly less intraoperative estimated blood loss and transfusion, lower nasogastric intubation rate, and earlier ambulation and recovery of intestinal function than the PDS group (P<0.05).

Conclusions

NAC/IDS is less invasive than PDS, and offers the advantages regarding optimal cytoreduction rate, intraoperative blood loss, and postoperative recovery, without significantly impairing the survival compared with PDS in treating patients with stage IIIC or IV EOC. Therefore, NAC/IDS may be a valuable treatment alternative for EOC patients.

Key Words

Epithelial ovarian cancerdebulking surgeryneoadjuvant chemotherapyperioperative morbiditysurvival

Copyright information

© Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gynecologic OncologyPeking University Cancer Hospital & InstituteBeijingChina
  2. 2.Department of Gynecologic OncologyPeking University Cancer Hospital & InstituteBeijingChina